# Frank S. Czerwiec

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/frank-s-czerwiec/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,017 |
| Field | Genetic and Kidney Cyst Diseases |
| h-index | 37 |
| i10-index | 53 |
| Last Known Institution | University of Portland |
| OpenAlex ID | https://openalex.org/A5016444110 |
| Works | 92 |

## Researcher papers

- [Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease](https://scholariq.org/papers/tolvaptan-in-patients-with-autosomal-dominant-polycystic-kidney-disease/)
- [Tolvaptan, a Selective Oral Vasopressin V <sub>2</sub> -Receptor Antagonist, for Hyponatremia](https://scholariq.org/papers/tolvaptan-a-selective-oral-vasopressin-v-sub-2-sub-receptor-antagonist-for/)
- [Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease](https://scholariq.org/papers/tolvaptan-in-later-stage-autosomal-dominant-polycystic-kidney-disease/)
- [Vasopressin V <sub>2</sub> -Receptor Blockade With Tolvaptan in Patients With Chronic Heart Failure](https://scholariq.org/papers/vasopressin-v-sub-2-sub-receptor-blockade-with-tolvaptan-in-patients-with/)
- [Oral Tolvaptan Is Safe and Effective in Chronic Hyponatremia](https://scholariq.org/papers/oral-tolvaptan-is-safe-and-effective-in-chronic-hyponatremia/)
- [Prevalence of autosomal dominant polycystic kidney disease in the European Union](https://scholariq.org/papers/prevalence-of-autosomal-dominant-polycystic-kidney-disease-in-the-european-union/)
- [Clinical Pattern of Tolvaptan-Associated Liver Injury in Subjects with Autosomal Dominant Polycystic Kidney Disease: Analysis of Clinical Trials Database](https://scholariq.org/papers/clinical-pattern-of-tolvaptan-associated-liver-injury-in-subjects-with-autosomal/)
- [Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion](https://scholariq.org/papers/efficacy-and-safety-of-oral-tolvaptan-therapy-in-patients-with-the-syndrome-of/)
- [Multicenter, open-label, extension trial to evaluate the long-term efficacy and safety of early versus delayed treatment with tolvaptan in autosomal dominant polycystic kidney disease: the TEMPO 4:4 Trial](https://scholariq.org/papers/multicenter-open-label-extension-trial-to-evaluate-the-long-term-efficacy-and/)
- [Cilostazol as a Unique Antithrombotic Agent](https://scholariq.org/papers/cilostazol-as-a-unique-antithrombotic-agent/)

## Researcher topics

- [Genetic and Kidney Cyst Diseases](https://scholariq.org/topics/genetic-and-kidney-cyst-diseases/)
- [Electrolyte and hormonal disorders](https://scholariq.org/topics/electrolyte-and-hormonal-disorders/)
- [Hormonal Regulation and Hypertension](https://scholariq.org/topics/hormonal-regulation-and-hypertension/)
- [Ion Transport and Channel Regulation](https://scholariq.org/topics/ion-transport-and-channel-regulation/)
- [Cerebrospinal fluid and hydrocephalus](https://scholariq.org/topics/cerebrospinal-fluid-and-hydrocephalus/)

## Researcher university

- [University of Portland](https://scholariq.org/institutions/university-of-portland/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.